why choose us

First received: September 13, 2022

Clinical Trial: Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).

Study Status: Completed

Recruit Status: RECRUITING

Condition: Liver Cirrhosis

Study Type: INTERVENTIONAL


Official Title: Evaluation of Prolonged-release Pirfenidone in Patients With Viral C Hepatitis, With Sustained Viral Response and Advanced Residual Liver Fibrosis. Potential Role of Epigenetics to Understand Therapeu

Brief Summary: Prolonged-Release Pirfenidone (PR-PFD) is an anti-fibrogenic and anti-inflammatory molecule used for the treatment of idiopathic pulmonary fibrosis (approved by FDA) and liver fibrosis (approved in Mexico by COFEPRIS).PFD effects are mediated in part through inhibition of TGF?, TNF?, IL-1 and IL-6, along with NF?B activation down-regulation causing reduced TNF? and IFN? levels.The aim of this protocol is to know if the epigenetic factors induced by PR-PFD have a regulatory role to understand the progression…

Read more